MedTrace Logo

Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance

NCT01191099 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2011-11-08

No results posted yet for this study

Summary

A single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancer

Conditions

Interventions

DEVICE

Pimonidazol

0.5gm/m2 Pimonidazol i.v. 16-24 hours before prostatectomy

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • 01 Studienregister MasterAdmins · UniversitaetsSpital Zuerich

  • Michael Müntener, MD · University Hospital Zurich, Division of urology

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2012-08-31
Completion
2020-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01191099 on ClinicalTrials.gov